Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study
Titel:
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study
Auteur:
de Marinis, F. Kim, T.M. Bonanno, L. Cheng, S. Kim, S.-W. Tiseo, M. Chu, Q. Proto, C. Sacher, A. Luo, Y.-H. Novello, S. Hao, D. Baik, C. Bazhenova, L. Lee, J.S. Cho, B.C. Cadranel, J. Diep, T.B. Metro, G. Narayanan, P. Yoneshima, Y. de Castro CarpeƱo, J. Baldotto, C. Nyhus, C. Yang, J.C.-H. Sequist, L.V. Levy, B. Hartmaier, R. Igwegbe, I. Poole, L. Xu, W. Ahn, M.-J.